Invention Grant
- Patent Title: CACNA1H-derived tumor antigen polypeptide and use thereof
-
Application No.: US16338126Application Date: 2016-09-30
-
Publication No.: US11548925B2Publication Date: 2023-01-10
- Inventor: Guanglei Li , Yong Hou , Shuntao Luo , Xiumei Lin , Ting An , Bo Li , Wei Zhang , Chengchi Chao , Zhen Cheng , Handong Li , Naibo Yang
- Applicant: Genoimmune Therapeutics Co., Ltd.
- Applicant Address: CN Hubei
- Assignee: Genoimmune Therapeutics Co., Ltd.
- Current Assignee: Genoimmune Therapeutics Co., Ltd.
- Current Assignee Address: CN Hubei
- Agency: Panitch Schwarze Belisario & Nadel LLP
- Agent Stephany G. Small; Lars H. Genieser
- International Application: PCT/CN2016/100978 WO 20160930
- International Announcement: WO2018/058489 WO 20180405
- Main IPC: C07K14/47
- IPC: C07K14/47 ; A61P35/00 ; G01N33/574 ; A61K39/00 ; C07K14/705

Abstract:
Provided are a tumor antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding the same; a nucleic acid construct, an expression vector, and a host cell containing the encoding nucleic acid; and an antigen presenting cell presenting the tumor antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.
Public/Granted literature
- US20200024316A1 CACNA1H-DERIVED TUMOR ANTIGEN POLYPEPTIDE AND USE THEREOF Public/Granted day:2020-01-23
Information query